This site is intended for healthcare professionals
Lead from the frontline: Optimizing first-line treatment selection in Ph+ ALL
CME-accredited symposium at the 2023 ASCO® Annual Meeting

Lead from the frontline: Optimizing first-line treatment selection in Ph+ ALL

Watch the hour-long symposium and complete the evaluation form to gain 1 CME credit
Read time: 60 mins
Last updated: 30th Jun 2023
Published:30th Jun 2023

Welcome to this CME-accredited symposium from the 2023 ASCO® Annual Meeting where Drs. Elias Jabbour, Hagop Kantarjian and Nicholas Short discuss frontline treatment options for Ph+ ALL. To gain your CME credit, follow all prompts: first, test your knowledge on the topics covered in this session by answering the questions below, then watch the 60-minute symposium and complete the final assessments.

Learning objectives

After participating in this educational activity, you will be able to:

  • Recall frontline treatment approaches for Ph+ ALL
  • State best practice recommendations for the implementation of MRD assessment to guide disease management in Ph+ ALL
  • Describe the impact of T315I mutations on treatment resistance in Ph+ ALL
  • Identify risk factors for relapse in Ph+ ALL

Target audience

This activity has been designed to meet the educational needs of hematologic and general oncologists, as well as nurses, advanced practitioners and pharmacists in contact with patients with Ph+ ALL.

Elias Jabbour, MD (Chair).pngElias Jabbour, MD (Chair)

Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia.

Over the past 5 years, Dr. Jabbour has assisted in developing chemotherapeutic and biologic agents in leukemias and has contributed to the development of others, including the Hyper CVAD-ofatumumab regimen in ALL, clofarabine in myeloid malignancies, hypomethylating agents in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), tyrosine kinase therapy in chronic myeloid leukemia (CML), and triple therapy in AML.

Dr. Jabbour has authored or co-authored hundreds of peer-reviewed medical publications and has served on the editorial boards of several scientific journals.

Hagop Kantarjian, MD.pngHagop Kantarjian, MD

Dr. Kantarjian joined the MD Anderson Cancer Center faculty after a hematology-oncology fellowship at MD Anderson in 1981–1983, becoming Professor of Medicine in 1993. In 1995, he was named Chair of the Department of Leukemia, and currently holds the Samsung Distinguished University Chair in Cancer Medicine.

Dr. Kantarjian is known for his practice-changing clinical-translational research in leukemia. Over the past four decades, his research has transformed some standards of care and dramatically improved survival in several leukemia subtypes, including ALL, CML, AML, and MDS.

Dr. Kantarjian has published more than 2,200 peer-reviewed manuscripts and more than 100 chapters. He is the Senior Editor of the four editions of the “MD Anderson Manual of Medical Oncology.” In 2000, he created the MD Anderson Leukemia Fellowship, which now trains about 10 fellows in leukemia annually, and he is heavily involved in mentoring and education. In 2012, he co-founded the Society of Hematologic Oncology (SOHO), which has now expanded worldwide. He is a non-resident fellow in healthcare at the Rice Baker Institute and has written extensively on important healthcare issues in cancer, including high cancer drug prices; the importance of universal equitable healthcare; healthcare safety nets and healthcare as a human right; drug shortages; and the value of the Affordable Care Act.

Nicholas Short, MD.pngNicholas Short, MD

Dr. Nicholas Short is an Assistant Professor in the Department of Leukemia at the MD Anderson Cancer Center. Dr. Short is a clinical and translational investigator in adult leukemias, with a particular emphasis on measurable residual disease (MRD) and the development of Phase 1 and 2 clinical trials of novel agents and combinations for patients with acute leukemias.

Dr. Short has authored over 125 peer-reviewed manuscripts and numerous abstracts that have been presented at national and international conferences, including the American Society of Hematology (ASH) Annual Meeting and Exposition, and the American Society of Clinical Oncology (ASCO) Annual Meeting.

For his accomplishments in the field of leukemia research, he has received a number of awards, including the ASCO Young Investigator Award and the ASH Junior Faculty Scholar Award in Clinical Research.


USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

Elias Jabbour, MD, disclosures: Employee or independent contractor relationship with Adaptive Biotechnologies, Novartis, Amgen, Takeda, Pfizer Inc., Astellas Pharma Inc., Sanofi, and BeiGene. Consultant relationship with Pfizer Inc., GSK, NKARTA, Sanofi. Grants or research support from Takeda Oncology, Astellas Pharma Inc., Xencor, Stemline Therapeutics, and NextCure.

Hagop Kantarjian, MD, disclosures: Grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz, Novartis, and Pfizer; Honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, AstraZeneca, Ipsen Biopharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision BioSciences, and Taiho Pharma

Nicholas Short, MD, disclosures: Consultant for Pfizer Inc., Jazz Pharmaceuticals, and Sanofi. Research grants from Takeda Oncology, Astellas Pharma Inc., Xencor, and Stemline Therapeutics. Honoraria from Novartis, Amgen, Astellas Pharma Inc., Sanofi, and BeiGene.

Reviewer Alicia Canalejo, MSN, APRN-C has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and EPG Health, an IQVIA business, staff have no relevant financial interests/relationships or affiliations in relation to this activity.

Requirements for successful completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and EPG Health, an IQVIA business. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this live event for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (

Advanced practice providers

Physician Assistants may claim a maximum of 1 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Date of original release: June 3, 2023. Date credit expire: June 3, 2024.

If you have any questions regarding credit please contact

This activity is funded by:

An independent medical education grant from Takeda.

This activity is jointly provided by USF Health and EPG Health, an IQVIA business.

The information provided by this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CE to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

5 minutes on the leukemia landscape with Dr Elias Jabbour

  • unmet needs for people with Ph+ ALL
  • recent practice-changing updates
  • the importance of a multidisciplinary approach
  • the future for people with Ph+ ALL

Learn more


This content has been developed independently of the sponsor, Takeda, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or the Conquer Cancer®, the ASCO Foundation.